Physicians' Academy for Cardiovascular Education

Identifying patients for PCSK9 therapy

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 16, 2019 - Kees Hovingh, MD – Amsterdam University Medical Centers, The Netherlands

This video is part of an educational series of four lectures focussed on PCSK9: Outcomes and trials in clinical perspective. In this module, prof. Hovingh discusses how to identify high risk patients for whom PCSK9 inhibitors might be considered.

Video navigation menu

  • Why do we need additional lipid lowering? 00:21
  • What is known about PCSK9 inhibition so far? 02:10
  • Which patients would benefit most from PCSK9 inhibition? 07:33
  • Highest risk-highest benefit strategy for PCSK9 inhibitor use 10:12
  • Clinical decision algorithm for use of PCSK9 inhibitors in patients with/without ASCVD 13:06

Educational information

This educational video is the first part of a series called "PCSK9: Outcomes and trials in clinical perspective" that are aimed to give cardiologists in secondary care and other healthcare professionals with an interest in treating patients with cardiovascular disease a well-balanced expert view on the current state of the art about the impact of PCSK9 inhibition on lipids and cardiovascular risk

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Other topics covered in this series

Other lectures part of this educational series are:

Faculty

Kees Hovingh, MD - Internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands and visiting professor at Imperial college in London, UK

CME Accreditation

This course is applied for online CME accreditation at EBAC (European Board for Accreitation in Cardiology). Once accredited the CME programme will be available in our CME section

Disclosures

This educational series is funded by an unrestricted educational grant provided by Sanofi-Regeneron.

View slides of prof. Hovingh

Share this page with your colleagues and friends: